Anti-Lung Resistancerelated Protein monoclonal antibody, clone MSQ-57

Lotus II, a randomized, open-label, multicenter, international study compared the efficacy and safety of oral dydrogesterone versus micronized vaginal progesterone (MVP) gel for luteal support in IVF. A prespecified subgroup analysis was performed on 239 Chinese mainland subjects from the overall study population (n = 1034), who were randomized to oral dydrogesterone 30 mg or 8% MVP gel 90 mg daily from the day of oocyte retrieval until 12 weeks of gestation. The aim was to demonstrate non-inferiority of oral dydrogesterone to MVP gel, assessed by the presence of a fetal heartbeat at 12 weeks of gestation. In the Chinese mainland subpopulation, there was a numerical difference of 9.4% in favor of oral dydrogesterone, with ongoing pregnancy rates at 12 weeks of gestation of 61.4% and 51.9% in the oral dydrogesterone and MVP gel groups, respectively (adjusted difference, 9.4%; 95% CI: -3.4 to 22.1); in the overall population, these were 38.7% and 35%, respectively (adjusted difference, 3.7%; 95% CI: -2.3 to 9.7). In both the Chinese mainland subpopulation and the overall population, dydrogesterone had similar efficacy and safety to MVP gel. With convenient oral administration, dydrogesterone has potential to transform luteal support treatment.

An ultralow-power and low-complexity impulse radio ultrawideband (IR-UWB) transmitter (TX) is fabricated in the low-cost 180-nm United Microelectronics Corporation (UMC) CMOS technology. The TX offers control of the power spectral density (PSD) by using a tunable pulse generator and a controllable switched oscillator. It supports on-off keying (OOK) coding and occupies a total die area of 0.35 mm(2). The measured results show the transmitter output amplitude of 130 mVp-p with the pulse width of 1.0 ns, and the PSD with 10-dB bandwidth from 3 to 8.8 GHz. The total dc power consumption is 0.6 mW, corresponding to the energy consumption of 3 pJ/pulse at 200-MHz pulse repetition frequency.